• National
  • Politics
  • Valley
  • Opinion
  • Money
  • Sports
  • Culture & Lifestyle

  • National
    • Madhesh Province
    • Lumbini Province
    • Bagmati Province
    • National Security
    • Koshi Province
    • Gandaki Province
    • Karnali Province
    • Sudurpaschim Province
  • Politics
  • Valley
    • Kathmandu
    • Lalitpur
    • Bhaktapur
  • Opinion
    • Columns
    • As it is
    • Letters
    • Editorial
    • Cartoon
  • Money
  • Sports
    • Cricket
    • Football
    • International Sports
  • Culture & Lifestyle
    • Arts
    • Brunch with the Post
    • Movies
    • Life & Style
    • Theater
    • Entertainment
    • Books
    • Fashion
  • Health
  • Food
    • Recipes
  • Travel
  • Investigations
  • Climate & Environment
  • World
  • Science & Technology
  • Interviews
  • Visual Stories
  • Crosswords & Sudoku
  • Horoscope
  • Forex
  • Corrections
  • Letters to the Editor
  • Today's ePaper
Tuesday, July 29, 2025

Without Fear or FavourUNWIND IN STYLE

22.96°C Kathmandu
Air Quality in Kathmandu: 78
300+Hazardous
0-50Good
51-100Moderate
101-150Unhealty for Sensitive Groups
151-200Unhealthy
201-300Very Unhealthy
Tue, Jul 29, 2025
22.96°C Kathmandu
Air Quality in Kathmandu: 78
  • What's News :

  • Nepal’s steel exports
  • Nepal’s tiger conservation efforts
  • Bayalpata Hospital takeover
  • Faecal coliform contamination
  • Disputes over land bill

World

Pfizer says pandemic could extend to 2024, vaccine data for younger children delayed

Early data suggests that three doses of the shot may be necessary to protect against the Omicron variant. Pfizer says pandemic could extend to 2024, vaccine data for younger children delayed
 Reuters
bookmark
  • facebook
  • twitter
  • Whatsapp
  • mail
Reuters
Published at : December 18, 2021
Updated at : December 18, 2021 10:40

Pfizer Inc on Friday forecast that the COVID-19 pandemic would not be behind us until 2024 and said a lower-dose version of its vaccine for 2- to 4-year-olds generated a weaker immune response than expected, potentially delaying authorization.

Pfizer Chief Scientific Officer Mikael Dolsten said in a presentation to investors that the company expects some regions to continue to see pandemic levels of Covid-19 cases over the next year or two. Other countries will transition to "endemic" with low, manageable caseloads during that same time period.

By 2024, the disease should be endemic around the globe, the company projected.

"When and how exactly this happens will depend on evolution of the disease, how effectively society deploys vaccines and treatments, and equitable distribution to places where vaccination rates are low," Dolsten said. "The emergence of new variants could also impact how the pandemic continues to play out."

Pfizer developed its Covid-19 vaccine with Germany's BioNTech SE, and currently expects it to generate revenue of $31 billion next year. It plans to make 4 billion shots next year.

The drugmaker also has an experimental antiviral pill called Paxlovid which reduced hospitalizations and deaths in high-risk individuals by nearly 90% in a clinical trial. Three analysts estimate sales of $15 billion to $25 billion for it next year, according to IBES data from Refinitiv.

Pfizer's forecast came after the emergence of the Omicron variant last month, which has more than 50 mutations compared with the original version of the virus. That has reduced the effectiveness of two doses of the vaccine against infection, and spurred fear of rapid spread around the globe.

Prior to the Omicron variant, top US disease doctor Anthony Fauci forecast the pandemic would end in 2022 in the United States.

Pediatric Vaccine

The Pfizer vaccine is authorized in the United States for people age 5 and older. But it said on Friday that its study in children between the ages of 2 and 4 who were given two 3-microgram doses of the vaccine found it did not create the same immune response that a larger dose of the vaccine had in older children.

The 3-microgram dose did generate a similar immune response in children aged 6 to 24 months, the company said.

The company said it will now test a three-dose course in both age groups, as well as in older children. It had previously expected data from 2- to 4-year-olds this year, but said it did not expect the delay would meaningfully change plans to file for emergency use authorization in the second quarter of 2022.

Pfizer and BioNTech have also been developing a version of their vaccine tailored to combat the quick-spreading Omicron variant, although they have not decided whether it will be needed. They expect to start a clinical trial for the updated vaccine in January, Pfizer executives said.

Variant-specific shots, if needed, could boost sales in 2022.

The highly-transmissible Omicron variant of the coronavirus has been detected in over 77 countries and has spread to about one-third of US states.

The vaccine was around 95% effective in the adult clinical trial, but Pfizer has said that immunity wanes some months after the second dose. Early data suggests that three doses of the shot may be necessary to protect against the Omicron variant.


Related News

Gunman kills four, including police officer, in Manhattan skyscraper, then takes own life
Defence minister denies India bowed to pressure to end fighting with Pakistan
More aid needed to tackle famine-like conditions in Gaza, says WFP
Thai, Cambodian leaders agree to ceasefire after five days of battle
North Korea calls South Korea’s peace overtures ‘great miscalculation’
At least six killed in shooting incident in Bangkok

Most Read from World

At least 19 killed as Bangladesh air force plane crashes into college campus
Evidence shows Jeju Air pilots shut off less-damaged engine before crash, source says
London Southend Airport closed, all flights cancelled after small plane crash
Russian plane goes missing in far east with nearly 50 aboard
Air India cockpit recording suggests captain cut fuel to engines before crash, source says

Editor's Picks

Kailash pilgrims breathe new life into Nepal’s mountain economy
Pressure groups are dictating lawmaking
Indians paying by QR in Nepal for a year but Nepalis still lack access in India
UML weighs binning age, term limits amid Oli-Bhandari rivalry
Law in the works to check officials’ conflict of interest

E-PAPER | July 29, 2025

  • Read ePaper Online
ABOUT US
  • About the Post
  • Masthead
  • Editorial Standards & Integrity
  • Workplace Harassment Policy
  • Privacy Policy
READ US
  • Home Delivery
  • ePaper
CONTACT US
  • Write for the Post
  • Letters to the Editor
  • Advertise in the Post
  • Work for the Post
  • Send us a tip
INTERACT WITH US
  • Twitter
  • Facebook
  • Instagram
OUR SISTER PUBLICATIONS
  • eKantipur
  • saptahik
  • Nepal
  • Nari
  • Radio Kantipur
  • Kantipur TV
© 2025 www.kathmandupost.com
  • Privacy Policy
Top